Page 10075
Nov 16, 2017
War between Iran & Saudi Arabia could send oil to $300 per barrel & impoverish the world
Posted by John Gallagher in category: economics
A war between Iran and Saudi Arabia would have a major impact on oil markets and the global economy. Crude will jump fivefold to $300 per barrel.
Nov 16, 2017
Traveling back in time could be possible, physicist says
Posted by John Gallagher in categories: cosmology, particle physics, robotics/AI, time travel, transportation
As the common tropes of science fiction continue to break out into reality, from humanoid robots to self-driving cars, there’s one concept that has seemingly remained beyond our grasp: time travel.
But, jumping through time might not be impossible, after all, according to one astrophysicist.
Continue reading “Traveling back in time could be possible, physicist says” »
They taught ATLAS Kung Fu 😮
Really impressive, only things that need to be worked on. Shrink the Torso A Lot, so it’s comparable to a person. And, someone is going to have finance coming up with a set of robotic human like hands.
Nov 16, 2017
Keystone pipeline shut down after spilling 5,000 barrels of oil in South Dakota
Posted by Genevieve Klien in categories: energy, materials
Not good!
Workers took the Keystone oil pipeline offline on Thursday after it spilled 5,000 barrels of oil in rural South Dakota, officials said.
A TransCanada crew shut down the pipeline at 6 a.m. Thursday morning after detecting an oil leak along the line, the company said. The leak was detected along a stretch of the pipeline about 35 miles south of a pumping station in Marshall County, South Dakota.
Continue reading “Keystone pipeline shut down after spilling 5,000 barrels of oil in South Dakota” »
Nov 16, 2017
The Devel Sixteen hypercar, and its 5,000-hp engine, are real
Posted by Carse Peel in category: military
Devel revealed the final concept version of the Sixteen, a jet fighter-inspired dragster that takes aim at 300 mph, thanks to a 5,000-hp engine.
Nov 16, 2017
World’s first ‘space nation’ Asgardia launches satellite into space
Posted by Carse Peel in category: satellites
It’s the end of the road for the protons this year after a magnificent performance from the Large Hadron Collider (LHC). On Friday, the final beams of the 2017 proton run circulated in the LHC. The run ended, as it does every year, with a round up of the luminosity performance, the indicator by which the effectiveness of a collider is measured and on which the operators keep a constant eye.
The LHC has far exceeded its target for 2017. It has provided its two major experiments, ATLAS and CMS, with 50 inverse femtobarns of data, i.e. 5 billion million million collisions. The inverse femtobarn (fb-1) is the unit used to measure integrated luminosity, or the cumulative number of potential collisions over a given period.
This result is all the more remarkable because the machine experts had to overcome a serious setback. A vacuum problem in the beam pipe of a magnet cell limited the number of bunches that could circulate in the machine. Several teams were brought in to find a solution. Notably, the arrangement of the bunches in the beams was changed. After a few weeks, luminosity started to increase again.
Nov 16, 2017
China sets 2020 date for world’s fastest wind tunnel
Posted by Carse Peel in category: military
China is developing aircraft capable of reaching US shores with nuclear warheads in just 14 minutes, reports suggest.
The craft will be capable of hypersonic flight speeds of up to 27,000 miles per hour (43,200 kmh) — 35 times the speed of sound.
Continue reading “China sets 2020 date for world’s fastest wind tunnel” »
Nov 16, 2017
The FDA Just Approved Another Promising Immunotherapy For Cancer
Posted by Ian Hale in categories: biotech/medical, genetics
On Wednesday—for only the second time—the Food and Drug Administration approved a cutting-edge therapy that genetically modifies a patient’s blood cells in order to attack cancer. This time the therapy, known as CAR T-cell therapy, is designed to treat aggressive non-Hodgkin lymphoma.
In August, the FDA approved the first CAR T-cell therapy, for a drug called Kymriah designed for children and young adults whose leukemia doesn’t respond to standard treatments. The FDA’s approval of Yescarta, manufactured by Kite Pharma, comes just a few months after its first approval—an indication of just how quickly the field of immunotherapy is moving. Several other companies also have CAR-T therapies in the works.